Abstract:BACKGROUND: Angiogenesis, the growth of new blood vessels, plays an important role in tumor growth and metastasis. Both cetuximab and endostatin have been found to reduce the expression of endothelial-stimulating growth factors such as vascular endothelial growth factor (VEGF) and interleukin (IL)-8. However, the effects of cetuximab alone or in combination with endostatin on human lung adenocarcinoma cell growth remain unclear.OBJECTIVE: The aim of this study was to evaluate the cellular and molecular effects of cetuximab alone and in combination with endostatin on human lung adenocarcinoma cell lines H1299, SPC-A1, and H460 in vitro.METHODS: The epidermal growth factor receptor (EGFR) status of a panel of human lung adenocarcinoma cell lines was characterized using Western blot analysis. We used a modified tetrazolium salt assay to evaluate the growth-inhibitory effects of cetuximab and endostatin alone and in combination on the cell lines. We also determined the effects of these 2 drugs on VEGF and IL-8 expression using enzyme-linked immunosorbent assay (ELISA) and Western blot analysis. Cells were treated for 4 days with cetuximab 12.5 mu g/mL, endostatin 25 mu g/mL, or cetuximab 12.5 mu g/mL + endostatin 25 mu g/mL. Untreated cells cultured for 4 days served as controls.RESULTS: EGFR expression in the HI 299 cells was higher than in the SPC-A1 and H460 cells. Varying concentrations of cetuximab alone were associated with a significant growth-inhibitory effect on all 3 cell lines in a dose-dependent manner after 4 days of exposure compared with controls (all, P < 0.05). Compared with controls, varying concentrations of endostatin alone were not associated with significant inhibition of cell growth in any of the 3 cell lines. The inhibitory ratio of cetuximab + endostatin at varying concentrations was significantly greater than that of cetuximab alone (all, P < 0.05). On ELISA, either drug alone was associated with significant reductions in secreted VEGF and IL-8 in the H1299, SPC-A1, and H460 cell lines (all, P < 0.05), with the exception of IL-8 concentration in the H460 cells. Mean (SD) VEGF expression with combination treatment in the H1299 and SPC-A1 cell lines (687 [21] and 629 [23] pg/mL, respectively) was significantly lower than with cetuximab alone (878 [31] and 708 [20] pg/mL; both, P < 0.001); in the H460 cell line, combination treatment was not associated with a significant further reduction in VEGF expression. IL-8 concentrations with cetuximab in the H1299, SPC-A1, and H460 cell lines were 628 (20), 484 (29), and 532 (28) pg/mL, respectively, while the IL-8 concentrations with the combination treatment were 516 (20), 480 (18), and 467 (30) pg/mL. An enhanced effect of endostatin on IL-8 was observed in the H1299 and H460 cell lines (P < 0.001 and P = 0.018, respectively); however, no enhanced effect in the SPC-A1 line was observed. Similar results for VEGF and IL-8 expression were found using Western blot analysis.CONCLUSIONS: The results from this in vitro study suggest that cetuximab treatment might both inhibit human lung adenocarcinoma cell line growth and reduce the expression of VEGF and IL-8, which are the biomarkers of angiogenesis. Endostatin was not associated with inhibition of human lung adenocarcinoma cell line growth directly. Findings with the combination of cetuximab + endostatin suggest that endostatin might enhance the antiangiogenic and antitumor activity of cetuximab through an apparent effect on VEGF expression and, to a lesser degree, on IL-8 expression. (Curr Ther Res Clin Exp. 2009;70:116-128) (C) 2009 Excerpta Medica Inc.

Effects of Anti-Egfr Monoclonal Antibody Cetuximab in Combination with the EGFR Tyrosine Kinase Inhibitor Gefitinib on Apoptosis of Human Pulmonary Adenocarcinoma Cells and Their Action Mechanism

The effects of cetuximab in combination with docetaxel for the acquired resistance to EGFR-TKI in non-small cell lung cancer cells

Combination of Cetuximab and Gefitinibto Therapy Non-Small Cell Lung Cancer(nsclc) in Vitro

Synergistic Effects of TOR Combined with EADM on Growth and Apoptosis in Human Lung Cancer Cell Lines A549 and H1299

(−)-Epigallocatechin-3-gallate derivatives combined with cisplatin exhibit synergistic inhibitory effects on non-small-cell lung cancer cells

[Effects of Monoclonal Antibody Cetuximab on Proliferation of Non-Small Cell Lung Cancer Cell Lines].

EGFR Inhibitors Sensitize Non-Small Cell Lung Cancer Cells to TRAIL-induced Apoptosis

Inhibition of Expression of Vascular Endothelial Growth Factor and Its Receptors in Pulmonary Adenocarcinoma Cell by TNP-470 in Combination with Gemcitabine

Sequence-dependent antiproliferative effects of gefitinib combined with docetaxel in non-small cell lung cancer cells in vitro

[Effects of Cetuximab Combined Erlotinib on Proliferation of Human Hepatocellular Carcinoma Cell Lines HepG2 and Bel-7402].

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

Association of CD8 T cell apoptosis and <i>EGFR</i> mutation in non-small lung cancer patients

EP1.03-11 Mechanisms of Gefitinib Plus Pemetrexed on Human Non-Small Cell Lung Cancer

Inhibition of EZH2 and EGFR produces a synergistic effect on cell apoptosis by increasing autophagy in gastric cancer cells.

The Synergistic Effect of EGFR Tyrosine Kinase Inhibitor Gefitinib in Combination with Aromatase Inhibitor Anastrozole in Non-Small Cell Lung Cancer Cell Lines

Apatinib to Enhance Antitumor Activity of Gefitinib in Non-Small Cell Lung Cancer.

Effect of Combination Treatment with L-carnitine and Epirubicin on Proliferation and Apoptosis in GLC-82 Cell and Its Mechanism

Apigenin Combined With Gefitinib Blocks Autophagy Flux and Induces Apoptotic Cell Death Through Inhibition of HIF-1α, c-Myc, p-EGFR, and Glucose Metabolism in EGFR L858R+T790M-Mutated H1975 Cells

Inhibitory effect and mechanism of gefitinib combined with metformin on EGFR-TKI intrinsic resistant NSCLC H1975 cells

The Efficacy of Combining EGFR Monoclonal Antibody with Chemotherapy for Patients with Advanced Nonsmall Cell Lung Cancer

The Effects of Cetuximab Alone and in Combination with Endostatin on Vascular Endothelial Growth Factor and Interleukin-8 Expression in Human Lung Adenocarcinoma Cells